A Comparison of Alemtuzumab with Basiliximab Induction in Simultaneous Pancreas-Kidney Transplantation

Authors :: Magliocca, J. F.
Odorico, J. S.
Pirsch, J. D.
Becker, Y. T.
Knechtle, S. J.
Leverson, G. E.
Sollinger, H. W.
Source :: American Journal of Transplantation; August 2008, Vol. 8 Issue: 8 p1702-1710, 9p
Publication Year :: 2008
Abstract: Alemtuzumab is a humanized, rat monoclonal antibody directed against the CD52 antigen. After binding, alemtuzumab causes profound and durable depletion and has been successfully used as immune induction therapy for organ transplantation.

Full Text Access

Tools